Eye (Lond). 2026 Aug;40(12):1929-1934. doi: 10.1038/s41433-026-04612-z.
Summary
Post-Vabysmo nAMD IOI in 0.13% of injections (14 eyes, 10805 injections). Mostly anterior and steroid-responsive with good final VA.
Abstract
Purpose: To describe the clinical characteristics and outcomes of intraocular inflammation (IOI) following intravitreal faricimab injection in a real-world setting.
Methods: This retrospective single-centre cohort study evaluated eyes developing IOI following intravitreal faricimab injection. Clinical characteristics, SUN-graded inflammatory features, intraocular pressure (IOP) changes, and time to resolution were analysed.
Results: A total of 14 eyes from 13 patients developed IOI following intravitreal faricimab injection, corresponding to an incidence of 0.13% per injection. All eyes developed anterior chamber inflammation, with two-thirds also demonstrating associated vitritis. Fifty percent (7/14 eyes) presented with an IOP > 21 mmHg. Overall, IOP increased from baseline in 11/14 eyes (79%), with 5 eyes (36%) demonstrating a clinically significant rise of ≥10 mmHg. The severity of acute anterior uveitis and vitritis correlated positively with time to resolution, whereas the presence of hypertensive uveitis did not significantly affect resolution time. The mean time to resolution was approximately two months.
Discussion: This study provides a comprehensive characterisation of post-faricimab IOI, including detailed SUN-graded phenotyping, IOP outcomes, and recurrent inflammatory episodes. Greater inflammatory severity was associated with prolonged resolution time, while hypertensive features did not appear to influence inflammatory recovery.
